Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 186 participants.
Also called NCT01384747
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 186 participants
- Registry
-
NCT01384747
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Terminated
Technical summary
Registry record NCT01384747. Randomized; triple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2018-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Fimasartan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Seung-Jung Park
- Collaborator
- CardioVascular Research Foundation, Korea
- Collaborator
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct01384747- Content hash
6cf2f7d57820b0baee5f9934173b35aab173cf49051eeabb0dd07deba9e8fb50